SA516371223B1 - لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية - Google Patents

لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية Download PDF

Info

Publication number
SA516371223B1
SA516371223B1 SA516371223A SA516371223A SA516371223B1 SA 516371223 B1 SA516371223 B1 SA 516371223B1 SA 516371223 A SA516371223 A SA 516371223A SA 516371223 A SA516371223 A SA 516371223A SA 516371223 B1 SA516371223 B1 SA 516371223B1
Authority
SA
Saudi Arabia
Prior art keywords
mers
sequence
cov
ser
antigen
Prior art date
Application number
SA516371223A
Other languages
Arabic (ar)
English (en)
Inventor
بي. وينير ديفيد
موثوماني كاروبيا
واي. سارديساي نيرانجان
Original Assignee
انوفيو فارماسيوتيكالز، إنك.
ذي ترستيز أوف ذي يونيفيرستي أوف بنسلفانيا
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by انوفيو فارماسيوتيكالز، إنك., ذي ترستيز أوف ذي يونيفيرستي أوف بنسلفانيا filed Critical انوفيو فارماسيوتيكالز، إنك.
Publication of SA516371223B1 publication Critical patent/SA516371223B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SA516371223A 2013-11-29 2016-05-29 لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية SA516371223B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361910153P 2013-11-29 2013-11-29

Publications (1)

Publication Number Publication Date
SA516371223B1 true SA516371223B1 (ar) 2023-01-31

Family

ID=53199622

Family Applications (1)

Application Number Title Priority Date Filing Date
SA516371223A SA516371223B1 (ar) 2013-11-29 2016-05-29 لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية

Country Status (10)

Country Link
US (5) US10016497B2 (zh)
EP (1) EP3074051A4 (zh)
JP (1) JP6412131B2 (zh)
KR (2) KR20230122181A (zh)
CN (2) CN112057613A (zh)
AU (1) AU2014354797C1 (zh)
CA (1) CA2932055A1 (zh)
IL (3) IL276210B2 (zh)
SA (1) SA516371223B1 (zh)
WO (1) WO2015081155A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2961768A4 (en) 2013-03-01 2016-10-26 New York Blood Ct Inc IMMUNOGENIC COMPOSITION FOR CORONAVIRUS INFECTION OF MIDDLE EAST RESPIRATORY SYNDROME (MERS-VOC)
JP6412131B2 (ja) * 2013-11-29 2018-10-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア MERS‐CoVワクチン
US11103575B2 (en) 2014-02-28 2021-08-31 The New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
EP3045181B1 (en) * 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
WO2017044507A2 (en) * 2015-09-08 2017-03-16 Sirnaomics, Inc. Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
CN106397549B (zh) * 2016-10-11 2019-08-06 中国疾病预防控制中心病毒病预防控制所 MERS-CoV特异性多肽及其应用
WO2018089306A1 (en) 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
KR20180058206A (ko) * 2016-11-23 2018-05-31 에스케이케미칼 주식회사 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2019078600A1 (ko) * 2017-10-19 2019-04-25 (주)에이티젠 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
WO2021158248A1 (en) 2020-02-04 2021-08-12 Oyagen, Inc. Method for treating coronavirus infections
CN115867349A (zh) 2020-02-25 2023-03-28 艾诺奥医药品有限公司 针对冠状病毒的疫苗和使用方法
CN111378785A (zh) * 2020-03-12 2020-07-07 仁宽(上海)生物科技有限公司 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用
US11559577B2 (en) 2020-03-31 2023-01-24 Engimata, Inc. Immunogenic composition forming a vaccine, and a method for its manufacture
WO2021252604A1 (en) * 2020-06-09 2021-12-16 The Wistar Institute Of Anatomy And Biology Coronavirus disease 2019 (covid-19) combination vaccine
EP4178545A2 (en) * 2020-07-10 2023-05-17 Engimata, Inc Immunogenic composition forming a vaccine, and a method for its manufacture
US20230279361A1 (en) * 2020-07-27 2023-09-07 National University Corporation Shiga University Of Medical Science Method for in vitro proliferating virus belonging to family coronaviridae, method for producing neutralizing antibody to virus belonging to family coronaviridae, and method for producing infection model of severe acute respiratory syndrome coronavirus 2
UY39378A (es) * 2020-08-14 2022-01-31 Univ Wuerzburg J Maximilians Vacuna de salmonella para el tratamiento de coronavirus
WO2022046737A1 (en) * 2020-08-25 2022-03-03 The Wistar Institute Of Anatomy And Biology Intradermal mers-cov vaccine
WO2022051816A1 (en) * 2020-09-10 2022-03-17 The Council Of The Queensland Institute Of Medical Research Methods of determining immune response
CN116390749A (zh) * 2020-09-11 2023-07-04 曼珍公司 使用嵌合cd40配体和冠状病毒疫苗增强免疫力
EP4333887A1 (en) * 2021-05-05 2024-03-13 Inovio Pharmaceuticals, Inc. Vaccines against coronavirus and methods of use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
CA2337129A1 (en) 1998-07-13 2000-01-20 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
CA2369329A1 (en) 1999-05-10 2000-11-16 Gunter A. Hofmann Method of electroporation-enhanced delivery of active agents
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
WO2005017133A1 (en) * 2003-08-18 2005-02-24 Amsterdam Institute Of Viral Genomics B.V. Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
CN101098710A (zh) * 2004-06-02 2008-01-02 纽约血液中心 产生高度有效抗体的sars疫苗和方法
US20090069256A1 (en) * 2004-06-04 2009-03-12 Smith Larry R Enhancing protein expression
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
PL2324113T3 (pl) 2008-08-08 2018-08-31 Takeda Vaccines, Inc. Cząstki wirusopodobne zawierające złożone kapsydowe sekwencje aminokwasowe do zwiększonej reaktywności krzyżowej
CA2819552C (en) * 2010-12-09 2023-09-26 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
WO2013083847A2 (en) * 2011-12-09 2013-06-13 Institut Pasteur Multiplex immuno screening assay
JP6205359B2 (ja) * 2012-07-23 2017-09-27 有限会社生物資源研究所 ワクチン
WO2015042373A1 (en) 2013-09-19 2015-03-26 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
JP6412131B2 (ja) * 2013-11-29 2018-10-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア MERS‐CoVワクチン

Also Published As

Publication number Publication date
AU2014354797C1 (en) 2018-02-01
AU2014354797A1 (en) 2016-07-07
IL305392A (en) 2023-10-01
KR20160091350A (ko) 2016-08-02
IL276210A (en) 2020-09-30
CN105939730A (zh) 2016-09-14
WO2015081155A1 (en) 2015-06-04
IL245903B (en) 2020-08-31
EP3074051A4 (en) 2017-04-12
JP2016539946A (ja) 2016-12-22
US10016497B2 (en) 2018-07-10
EP3074051A1 (en) 2016-10-05
US20200222527A1 (en) 2020-07-16
IL276210B1 (en) 2023-09-01
US20170258893A1 (en) 2017-09-14
US20240123056A1 (en) 2024-04-18
US20210401972A1 (en) 2021-12-30
AU2014354797B2 (en) 2017-10-26
US10548971B2 (en) 2020-02-04
IL276210B2 (en) 2024-01-01
IL245903A0 (en) 2016-07-31
CN112057613A (zh) 2020-12-11
KR20230122181A (ko) 2023-08-22
US11801298B2 (en) 2023-10-31
US11135284B2 (en) 2021-10-05
US20190022213A1 (en) 2019-01-24
CA2932055A1 (en) 2015-06-04
JP6412131B2 (ja) 2018-10-24
CN105939730B (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
SA516371223B1 (ar) لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية
Martínez-Flores et al. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants
Weissman et al. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization
Planas et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization
Singh et al. Foot-and-mouth disease virus: immunobiology, advances in vaccines and vaccination strategies addressing vaccine failures—an Indian perspective
CN111671890A (zh) 一种新型冠状病毒疫苗及其应用
UA126848C2 (uk) Філовірусна вакцина на основі рекомбінантного модифікованого вірусу вісповакцини анкара (mva)
CN109152826A (zh) 新抗寨卡病毒疫苗
Sumirtanurdin et al. Coronavirus disease 2019 vaccine development: an overview
WO2021262672A1 (en) Sars-cov-2 rbd constructs
Wang et al. Vaccination with a single consensus envelope protein ectodomain sequence administered in a heterologous regimen induces tetravalent immune responses and protection against dengue viruses in mice
WO2022096899A1 (en) Viral spike proteins and fusion thereof
Zhao et al. Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
Sankaradoss et al. Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences
WO2023023940A1 (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
Chi et al. Inactivated rabies virus vectored mers-coronavirus vaccine induces protective immunity in mice, camels, and alpacas
US20210093709A1 (en) Use of shrek proteins for inactivating viral infectivity and to produce live-attenuated vaccines against viruses
Starodubova et al. Cellular immunogenicity of novel gene immunogens in mice monitored by in vivo imaging
Hsieh et al. Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge
Wei et al. Generation and Characterization of Recombinant Pseudorabies Virus Delivering African Swine Fever Virus CD2v and p54
Zeng et al. Exploring the Potential of Cytomegalovirus-Based Vectors: A Review
Lien et al. Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern
Liu et al. Immunogenicity of recombinant BCGs expressing predicted antigenic epitopes of bovine viral diarrhea virus E2 gene
Basingab et al. TOWARDS SUFFICIENT IMMUNITY: INSIGHT INTO SARS-COV-2 VACCINES BASED ON VIRUS STRUCTURE AND PROPERTIES.
Kamel et al. The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors